Comparative Pharmacology
Head-to-head clinical analysis: RENAGEL versus VELPHORO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RENAGEL versus VELPHORO.
RENAGEL vs VELPHORO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sevelamer is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and reducing serum phosphate levels.
Iron-based phosphate binder that forms non-absorbable complexes with dietary phosphate in the gastrointestinal tract, reducing serum phosphate levels.
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 1 tablet/capsule per meal based on serum phosphorus levels. Maintenance: typically 2-4 tablets/capsules per meal.
1-2 tablets (500-1000 mg iron) orally three times daily with meals; titrate to achieve serum phosphorus target.
None Documented
None Documented
Not applicable (non-absorbable polymer; systemic absorption <0.01%).
Not applicable (non-absorbed drug acting locally in GI tract; no systemic half-life).
Renal: 0%; Fecal: >99% (as intact drug, due to non-absorbable polymer). Biliary: negligible.
Primarily fecal as unabsorbed drug; negligible renal excretion (<0.1%).
Category C
Category C
Phosphate Binder
Phosphate Binder